NHS England gives patients with nmDMD access to Translarna
PTC Therapeutics and NHS England have successfully negotiated a Managed Access Agreement (MAA) for Translarna (ataluren) for ambulatory patients aged five years and older with nonsense mutation Duchenne muscular dystrophy (nmDMD).
Click on this link for more information.
